Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease

Study Overview
=================
Brief Summary
-----------------
A new Coronavirus (SARS-CoV-2) emerged in Wuhan Province, China in December 2019 and rapidly spread around the world. To date, the data in the literature regarding the clinical and epidemiological characteristics of severe forms of CoVid-19 in patients with chronic respiratory disease are not well known. The hypothesis is that patients with chronic respiratory disease (COPD, asthma, bronchial dilatations, pulmonary hypertension, cystic fibrosis, obesity-hypoventilation syndrome, obstructive sleep apnea syndrome) infected with SARS-Cov-2 will have increased dyspnea and hypoxemia leading to hospitalization for severe forms more frequently than the general population. However, they do not appear to be more at risk of developing a critical form. This study is carried out in order to propose to estimate the prevalence of critical forms of CoVid19 among patients with chronic respiratory diseases hospitalized for severe forms.

Official Title
-----------------
Evaluation of the Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease Hospitalized for Severe Forms

Conditions
-----------------
COVID

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age greater than or equal to 18 years of age Diagnosis of CoVid-2 SARS infection retained (from clinical presentation, radiological and CoVid-19 positive microbiological specimen). Hospitalisation in the conventional medical sector for respiratory reasons (= severe form of CoVid-19) in the Nancy-Brabois hospital and Metz-Thionville Hospital between 02/03/2020 and 15/06/2020. Exclusion Criteria: Diagnosis of SARS-CoV-2 infection not retained Refusal of the patient to participate in the study Persons referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code: o Pregnant woman, parturient or breastfeeding mother o Minors (not emancipated) o Persons of full age subject to a legal protection measure (guardianship, curatorship, safeguard of justice) - Persons of full age unable to express their consent Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care by virtue of articles L. 3212-1 and L. 3213-1.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients without chronic respiratory disease<br>All patients hospitalized for severe CoVid-19 without chronic respiratory disease | Other: no intervention<br>* There will be no intervention. It is only an observationnal study<br>|
| Patients with chronic respiratory diseas<br>Patients hospitalized for severe CoVid-19 with one chronic respiratory disease | Other: no intervention<br>* There will be no intervention. It is only an observationnal study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale | Value of 6 or greeter on WHO CoVid-19 scale, indicating of a critical form of CoVid-19. | up to 28 days (during hospitalisation) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determined potential predictive factors of critic form in patients with chronic lung diseases | Radiological damage (extension of ground-glass) could be a predictive factor. | up to 28 days (during hospitalisation) | 
| Determined percentage of death | intra-hospital death, intra-ICU death | up to 28 days (during hospitalisation) | 
| Determined duration of oxygen therapy | in days (or duration at a different flow rate compared to long-term home oxygen therapy prior to hospitalization) | up to 28 days (during hospitalisation) | 
| Determined duration of hospitalization | in days for patients with chronic respiratory disease between the date of admission and the date of discharge. Patients who died during hospitalization will be assigned the highest cohort value. | up to 28 days (during hospitalisation) | 
| Determine mean values of the WHO CoVid-19 infection progression scale measured | values will be measured at D3, D7 and D14 in each of the groups. Patients who do not reach D7 and D14 will have the last postponement | up to 28 days (during hospitalisation) |